| abstract |
The invention provides compounds, pharmaceutical compositions and methods comprising modified LCAT for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject. The modified LCAT having a replacement of the amino acid residue 31 by a cysteine residue. The cysteine residue being modified by replacing the thiol hydrogen with 3-pyrazinyl-2-carbonitrile. |